[US-헬스케어] 06/18 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate robust momentum, driven by its dominant position in the GLP-1 receptor agonist market. While current valuations appear stretched by traditional metrics, the market is pricing in significant long-term growth potential beyond its flagship obesity treatments. The company’s strategic diversification—evidenced by its $3.8 billion investment in vaccine manufacturing and advancements in its oncology pipeline (e.g., Jaypirca)—serves as a critical hedge against future patent cliffs and competitive pressures. Investors should monitor the sustainability of its operating margins as the company scales production to meet unprecedented global demand.

Novo Nordisk’s recent regulatory progress, specifically the EU backing for oral Wegovy, serves as a critical catalyst for the company’s long-term growth strategy. By transitioning from injectable to oral administration, the company is poised to significantly expand its addressable market and improve patient adherence, which is essential for maintaining its competitive moat in the GLP-1 receptor agonist space. Furthermore, the expansion into the UAE market underscores a successful international diversification strategy beyond the U.S. While minor stock price volatility and data security concerns persist, these are largely noise compared to the fundamental strength of the company’s pipeline commercialization and dominant market position in obesity care.

Amgen (AMGN) is currently demonstrating strong momentum, underscored by recent regulatory milestones and a strategic pivot toward high-growth therapeutic areas. The approval of Imdelltra (tarlatamab) for small-cell lung cancer represents a significant clinical victory, validating the company’s robust R&D pipeline and its ability to capture market share in the rare disease segment.

While investors are closely monitoring potential risks associated with Tepezza (Tavneos) and broader portfolio volatility, the recent upward price action suggests that the market is increasingly pricing in the long-term value of Amgen’s diversified biopharmaceutical portfolio. Despite a 24% year-over-year gain, the stock remains attractive for long-term investors, provided the company continues to execute its strategy of balancing legacy revenue streams with high-margin, innovative drug launches.

UnitedHealth Group (UNH) has recently demonstrated strong market momentum, driven by a combination of operational efficiency and improved cost management. The recent 5%+ surge in share price reflects investor confidence following the mitigation of medical cost ratios (MCR), which had previously pressured margins. Furthermore, the company’s strategic $1.6 billion investment in Artificial Intelligence (AI) is a critical catalyst, signaling a long-term commitment to optimizing administrative workflows and enhancing clinical outcomes. This technological pivot, coupled with a shareholder-friendly policy of dividend growth, reinforces UNH’s position as a defensive yet growth-oriented leader in the managed care sector. Despite historical divestment activity by institutional giants, the current upward revision in Wall Street ratings underscores a favorable risk-reward profile as the company successfully navigates regulatory and cost-related headwinds.

Pfizer (PFE) is currently at a critical inflection point as it pivots from post-pandemic volatility toward a sustainable growth model. The recent Q1 earnings beat, coupled with the advancement of its pipeline, suggests that the company is successfully stabilizing its core operations.

The primary catalysts for a potential re-rating include the expansion of HYMPAVZI (marstacimab) in the hematology space and the strategic development of its GLP-1 portfolio. While the stock faces headwinds regarding valuation and market sentiment, the current price point of ~$26 offers an attractive entry for investors looking for long-term value, provided the company continues to demonstrate clinical execution and successful commercialization of its new therapeutic assets.